Stockscreener 앱 받기
1.81
1.09%
-0.02
전일 마감가:
$1.83
열려 있는:
$1.85
하루 거래량:
352.26K
Relative Volume:
2.60
시가총액:
$21.32M
수익:
$28.74M
순이익/손실:
$-31.60M
주가수익비율:
-0.3563
EPS:
-5.0805
순현금흐름:
$-19.30M
1주 성능:
+16.03%
1개월 성능:
+50.83%
6개월 성능:
+57.39%
1년 성능:
+2.84%
1일 변동 폭
$1.75
$1.8699
1주일 범위
$1.41
$1.885
52주 변동 폭
$1.00
$2.23
바이오나노 지노믹스 Stock (BNGO) Company Profile
명칭
Bionano Genomics Inc
전화
(858) 888-7600
주소
9540 TOWNE CENTRE DRIVE, SAN DIEGO, CA
Compare BNGO vs ISRG, BDX, RMD, ALC, MDLN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BNGO
Bionano Genomics Inc
|
1.81 | 14.37M | 28.74M | -31.60M | -19.30M | -5.0805 |
ISRG
Intuitive Surgical Inc
|
401.91 | 130.41B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
181.78 | 48.44B | 21.37B | 1.41B | 3.07B | 3.9437 |
RMD
Resmed Inc
|
224.78 | 31.49B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
65.52 | 31.92B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.65 | 28.54B | 29.14B | 1.07B | 1.05B | 1.1956 |
바이오나노 지노믹스 Stock (BNGO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-15 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-09-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-12-12 | 재개 | BTIG Research | Buy |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2021-06-16 | 개시 | BTIG Research | Buy |
| 2020-09-24 | 개시 | Ladenburg Thalmann | Buy |
| 2020-04-08 | 개시 | Oppenheimer | Outperform |
모두보기
바이오나노 지노믹스 주식(BNGO)의 최신 뉴스
Local Coverage Determinations Roundup: ChromaCode, Biofidelity, Biocartis, Bionano Genomics - GenomeWeb
MolDX proposes Medicare coverage for Bionano genome mapping test - Investing.com
MolDX proposes Medicare coverage for Bionano genome mapping test By Investing.com - Investing.com Canada
Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms - The Manila Times
Bionano Genomics (BNGO) interim CEO adds 4,000 shares in IRA - Stock Titan
Bionano Laboratories Announces New York State Department of - GlobeNewswire
Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Moomoo
Bionano Genomics (NASDAQ:BNGO) Shares Turns Active on Today’s Market Trigger - Kalkine Media
Bionano Genomics Inc. Warrant (BNGOW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bionano Genomics Inc. Warrant (BNGOW) Peer Comparison – Compare with Others - Value Research
Bionano Genomics Inc. Warrant (BNGOW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Bionano Genomics Inc. Warrant (BNGOW) Key Financial Ratios – Valuation, Profitability & More - Value Research
Bionano Genomics Inc. (BNGO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Bionano Genomics Inc. (BNGO) Peer Comparison – Compare with Others - Value Research
Bionano Genomics (NASDAQ: BNGO) interim CEO buys 4,000 shares - Stock Titan
Bionano (BNGO) Q2 2026 Results: EPS Exceeds Its Estimate at the Close; Latest Reaction: Shares Fall 0.84% in Latest TradingLong-Term Guidance - vinanet.vn
Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors - qz.com
Bionano Genomics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Bionano Genomics (BNGO) Q2 2026 Earnings Call Transcript - AOL.com
Alex Reid Hastie Net Worth (2026) - GuruFocus
Bionano Genomics (BNGO) investor discloses 9.9% position via warrants - Stock Titan
Gossamer Bio: Q2 Earnings Snapshot - AOL.com
Analysts Offer Insights on Healthcare Companies: BioNano Genomics (BNGO), Liquidia Technologies (LQDA) and PolyPid (PYPD) - The Globe and Mail
Maxim Group Maintains Bionano Genomics(BNGO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Bionano Genomics Inc (BNGO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bionano Reports Second Quarter 2026 Results and Provides a Business Update - Moomoo
Bionano Genomics earnings beat by $0.13, revenue topped estimates - Investing.com Nigeria
Bionano Genomics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:BNGO) 2026-08-11 - Seeking Alpha
Bionano Genomics Q2 2026 Earnings Call Transcript - MarketBeat
Bionano Genomics Q2 Results: Revenue rises 21% to $8.2 million - scanx.trade
Bionano Genomics Inc (BNGO) (Q2 2026) Earnings Call Highlights: - GuruFocus
Bionano Genomics Inc (BNGO) (Q2 2026) Earnings Call Highlights: Record Flow Cell Sales and ... - Yahoo! Finance Canada
Bionano Genomics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Bionano Genomics Q3 Results: Sales guidance ranges $8.200M-$8.600M - scanx.trade
BNGO Looks 21.6% Undervalued on GF Value™ Despite Unprofitabilit - GuruFocus
BIONANO GENOMICS ($BNGO) Releases Q2 2026 Earnings - Quiver Quantitative
How Could Bionano Genomics (NASDAQ:BNGO) Influence Penny Stocks Sentiment? - Kalkine Media
Bionano Genomics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
BNGO: Record Q2 revenue and margin driven by clinical adoption, with growth limited by supply constraints - TradingView
Is Bionano Genomics Inc (BNGO) Undervalued After Q2 Earnings? EPS: -$7.4M, Revenue: $8.2M, GF Score: 64/100 - GuruFocus
Transcript : Bionano Genomics, Inc., Q2 2026 Earnings Call, Aug 10, 2026 - marketscreener.com
Earnings call transcript: Bionano Genomics tops Q2 revenue view, shares edge up - Investing.com
Bionano Genomics raises FY26 sales guidance range - scanx.trade
Q2 2026 Bionano Genomics Inc Earnings Call Transcript - GuruFocus
Bionano Genomics Q2 revenue rises on increased clinical adoption - TradingView
BNGO: Q2 2026 revenue rose 21% but liquidity concerns threaten ongoing operations - TradingView
Bionano Reports Q2 2026 Revenue of $8.2M, Gross Margin 53% - TradingView
Bionano Genomics, Inc. Q2 2026: Revenue $8.17M, EPS $(0.64) — 10-Q Summary - TradingView
Bionano Genomics (NASDAQ: BNGO) grows revenue amid going concern warning - Stock Titan
BRIEF-Bionano Genomics Q2 Revenue USD 8.2 Million - TradingView
Bionano Genomics, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2026 - marketscreener.com
바이오나노 지노믹스 (BNGO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오나노 지노믹스 주식 (BNGO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Luderer Albert | Interim Chief Executive |
Aug 21 '26 |
Buy |
1.22 |
4,000 |
4,860 |
4,000 |
3.18%
자본화:
|
볼륨(24시간):